comprehensive -WSS

comprehensive

author：fashion 2025-09-30 12:10:33 - browse：16224

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Change Healthcare cyberattack outage could last weeks

WSS

Scientists unlock the key to scar

Harvard scientists, with Google, unveil the most detailed brain map ever

Bird flu reported in person exposed to presumably infected cattle

Biotech companies concerned about China biosecurity crackdown

Covid silver lining: Unprecedented look at human immune system

Scientists unlock the key to scar

explore

comprehensive

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

The cancer drug shortage isn’t new — and neither are the solutions

Trial using CRISPR to edit HIV out of cells disappoints

Walensky prepares to leave CDC — and Congress — behind

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Supreme Court strikes down use of affirmative action

Alzheimer's risk factor APOE4 may be a distinct form of the disease

What does generative AI mean for health care? We asked experts

How to address the problem of discarded donor organs

focus

Covid isolation guidance eased by the CDC

ALS groups 'won't be played again' by the FDA, drug sponsors

How to fix the rural physician shortage in the U.S.

Covid silver lining: Unprecedented look at human immune system

Republican states more likely to report Covid vaccine side effects

In search for therapies for solid tumors, companies turn to claudin

knowledge

leisure time

explore

hotspot